A Huge Win for Michigan's Innovation Economy-R&D Tax Credit Reestablished

December 31, 2024

Michigan Revives R&D Tax Credit, Boosting Innovation and Support for Small Businesses

In a milestone for Michigan’s innovation economy, the legislature passed a long-awaited and long-fought Research & Development (R&D) Tax Credit legislation – fifteen years in the making!


It was a protracted, and at times frustrating, journey for MichBio in its advocacy to reestablish an economic development incentive specifically aimed at R&D in Michigan. We watched numerous other states bolster their life sciences industry with competitive R&D tax credits while Michigan languished as one of the very few without such an incentive. Reestablishment of a R&D Tax Credit was MichBio’s #1 policy priority going back to 2010.


Michigan will now be one of the many states that offer a state-level R&D tax credit with the passage of HBs 5099-5102, and 4368. Part of the package passed earlier this year, but the bills that contained the credit, HB 5100-5101, didn’t get passed until mid- November with a House vote of 86-23. The Senate only concurred the bills in the latter part of the lame duck.

The newly reestablished tax credit is a vast improvement over what Michigan offered previously. MichBio led the charge with key legislation author, Rep. Julie Rogers (D) towards ensuring that this time, the credit had funding separate for “small” companies who typically would get lost in the shuffle and walk away with no access to a credit because large companies had already leveraged all the funds. In addition, MichBio fought for a premium add-on credit amount for R&D work that was contracted with a Michigan university, thereby bolstering economic and technology ties between the private sector and our institutional research prowess.


The state credit would be combined with any federal R&D credits and will be capped at $100 million, with $25 million specifically for small businesses. Here are some details you need to kno wwhen considering this tax strategy. If a business is eligible for the federal credit, then the business may claim the credits based on the size of the business and collaboration with an eligible Michigan-based research university:

  • “Large” companies with 250 or more employees: a 10% credit, and the amount cannot exceed $2,000,000.
  • Small” companies as defined by having less than 250 employees: 15%, credit cannot exceed $250,000.
  • Companies can claim an additional 5% credit if working with a research university in the state, but the credit cannot exceed $200,000.
  • A business’s base amount is calculated by determining the annual QRE for the three years preceding the year the credit is utilized.


Gov. Whitmer is expected to sign the new legislation making the Michigan R&D Tax Credit effective January 1, 2025, and provide significant tax savings opportunities for businesses.

RECENT ARTICLES

April 24, 2025
Prenuptial Patenting: Responsible Engagement with Engineering Firms
April 24, 2025
PharmOptima, a Poratge, Michigan-based preclinical contract research organization (CRO) is advancing drug discovery through its comprehensive suite of services. Specializing in in-vivo ADME/PK, ocular research, as well as regulated large and small molecule bioanalytical and ligand binding services, PharmOptima supports clients in optimizing drug development programs efficiently and effectively. With a staff averaging 11 years of industry experience and multiple individuals with advanced degrees, PharmOptima also boasts one of the most capable and engaging teams in the industry. The company collaborates with board-certified veterinary ophthalmologist Dr. Ryan Boyd, further enhancing its ocular research capabilities. PharmOptima's team of experts is dedicated to providing high-quality services to the pharmaceutical biotechnology industries. Looking ahead, PharmOptima scientists will be presenting posters at the 2025 The Association for Research in Vision and Ophthalmology (ARVO) conference, showcasing their latest research and innovations in ocular drug development. For more information visit www.pharmoptima.com .
April 24, 2025
Two bills, HB 4332 and HB 4333 were recently re-introduced that would prohibit pathogen gain-of-function (GoF) research. Given that the House is now Republican-led raises concerns for MichBio and others that the legislation might gain traction due to misinformation over biosafety and pandemic origins. MichBio opposes such broad legislative bans as they risk undermining critical scientific progress, public health preparedness, and economic innovation. GoF research has been instrumental in developing life-saving therapies and vaccines. For instance, viral vector-based gene therapies, such as Sarepta's Elevidys for Duchenne muscular dystrophy, and oncolytic virotherapies like Amgen's Imlygic for melanoma, rely on genetically modified viruses to deliver therapeutic genes or selectively destroy cancer cells. These advancements stem from GoF methodologies that enhance viral capabilities for therapeutic purposes. Moreover, GoF research has played a pivotal role in vaccine development. Examples like the AstraZeneca and Janssen COVID-19 vaccines and Merck's ERVEBO vaccine against Ebola employs a genetically modified virus to confer protection, underscore the public health benefits derived from GoF studies. ​ Contrary to concerns that GoF research operates without sufficient oversight, multiple layers of regulation are in place. Since 2017, the U.S. Department of Health and Human Services has implemented a framework to evaluate and guide funding decisions for GoF research, particularly those involving potential pandemic pathogens. This framework includes stringent safety protocols, risk assessments, and ethical reviews. ​ MichBio is most concerned that any legislative bans that broadly define and prohibit GoF research risk stifling innovation across various scientific fields. Such bans could inadvertently encompass research in virology, microbiology, molecular biology, and synthetic biology—disciplines vital for developing new therapies, sustainable agricultural practices, and environmental remediation technologies. ​ In turn, state-level bans on GoF research could have detrimental effects on local economies and academic institutions. Such a ban could impede research critical to understanding and combating diseases, leading to a loss of federal and philanthropic funding. This could hamper the growth of the Michigan's biotech and biomedical sectors. ​  MichBio advocates for a balanced approach that reinforces existing oversight mechanisms and fosters transparent, responsible research practices essential to safeguard both public health and scientific progress.